– Gregg Alton Appointed Chief Patient
Officer –
– Diana Brainard, MD, Promoted to Senior
Vice President, HIV and Emerging Viral Infections –
– Andrew Cheng, MD, PhD, Chief Medical
Officer, to Leave Gilead –
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Gregg
Alton has been appointed Chief Patient Officer, a newly created
role that will facilitate access to the company’s medicines and
increase focus on reaching patients. The company also announced
that Diana Brainard, MD, has been promoted to Senior Vice
President, HIV and Emerging Viral Infections, and that Andrew
Cheng, MD, PhD, Chief Medical Officer, has decided to leave Gilead
to pursue another opportunity.
Mr. Alton joined the company nearly 20 years ago and was the
architect of its access program, which has enabled Gilead’s HIV
medicines to reach more than 11 million people in the developing
world. He has helped shape the organization in a number of
executive positions, including as general counsel, and more
recently, leading the company’s international commercial operations
and corporate affairs groups. Prior to joining Gilead, he was an
attorney at the law firm of Cooley Godward, LLP, where he
specialized in mergers and acquisitions, corporate partnerships,
and corporate finance transactions for healthcare and information
technology companies. Mr. Alton received a bachelor's degree from
the University of California, Berkeley, and holds a JD from
Stanford University.
“Gregg has a deep and broad understanding of the company and an
unparalleled commitment to enabling access to our medicines for
millions of people in both the developed and developing world,”
said John F. Milligan, PhD, President and Chief Executive Officer
of Gilead. “Bringing together into one organization a number of
groups – including Access Operations & Emerging Markets, Public
Affairs & Advocacy, Government Affairs, Medical Affairs,
Digital Patient Solutions and the company’s commercial operations
in certain countries in Asia – will help us better serve
patients.”
Dr. Brainard joined Gilead in 2010. She has extensive training
and experience in immunology, infectious diseases and drug
development. Under her leadership, Gilead received regulatory
approval of four chronic hepatitis C virus (HCV) therapies in a
period of less than four years. She was promoted to Vice President,
Clinical Research, Liver Diseases, in 2015. Dr. Brainard received a
bachelor’s degree from Brown University, holds an MD from Tulane
University School of Medicine, and completed her residency and
fellowship in internal medicine and infectious diseases at Harvard
University. Dr. Brainard trained as an infectious diseases
physician at Massachusetts General Hospital and was on faculty at
Harvard Medical School, where her NIH-funded research focused on
translational models and T-cell trafficking in HIV infection. In
addition to her clinical and research activities in Boston, she
helped establish an immunology laboratory and train researchers at
the Nelson R Mandela School of Medicine, University of
KwaZulu-Natal in Durban, South Africa.
“Diana is an astute, knowledgeable and experienced clinician and
researcher with broad expertise across the field of infectious
diseases. She played an instrumental role in the rapid clinical
development and approval of Gilead’s HCV medicines,” said John
McHutchison, MD, Chief Scientific Officer and Head of Research and
Development. “The vision and leadership that she brings to this
role will enable Gilead to continue to innovate, and advance new
therapies for people with HIV and other emerging viruses.”
Dr. Cheng joined Gilead in 1999 to lead the company’s
development-stage programs in HIV/AIDS. He received additional
responsibility for the company’s Development Operations
organization in 2009 and was named Executive Vice President in
2015. Dr. Cheng was appointed Chief Medical Officer in March.
“During his time at Gilead, Andrew played a definitive role in
bringing forward new medicines that transformed the lives of
millions of people with serious illnesses,” said Dr. Milligan.
“Andrew played an especially critical part in advancing our
portfolio of HIV products, and we’re extremely grateful for his
many contributions and wish him all the best in the future. We are
very pleased that Diana will lead this important therapeutic area
for us going forward, as we seek to advance our next generation of
HIV medicines, including potential options for prevention and
perhaps one day a cure.”
Dr. Cheng will remain at Gilead until September 7 to help with
the transition of his duties. Mr. Alton and Dr. Brainard will take
on their new roles effective immediately.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical
company that discovers, develops and commercializes innovative
medicines in areas of unmet medical need. The company strives to
transform and simplify care for people with life-threatening
illnesses around the world. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City,
California.
Forward-Looking
Statement
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks, uncertainties, and other factors. These
risks, uncertainties and other factors could cause actual results
to differ materially from those referred to in the forward-looking
statements. The reader is cautioned not to rely on these
forward-looking statements. These and other risks are described in
detail in Gilead’s Quarterly Report on Form 10-Q for the quarter
ended June 30, 2018, as filed with the U.S. Securities and Exchange
Commission. All forward-looking statements are based on information
currently available to Gilead, and Gilead assumes no obligation to
update any such forward-looking statements.
For more information on Gilead Sciences,
please visit the company’s website at www.gilead.com, follow
Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180814005715/en/
Gilead Sciences, Inc.Sung Lee, 650-524-7792InvestorsAmy Flood,
650-522-5643Media
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024